Gilead Sciences, Inc. (NASDAQ:GILD) Stake Boosted by GLOBALT Investments LLC GA

GLOBALT Investments LLC GA grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.3% in the 4th quarter, Holdings Channel reports. The firm owned 48,659 shares of the biopharmaceutical company’s stock after acquiring an additional 8,204 shares during the quarter. GLOBALT Investments LLC GA’s holdings in Gilead Sciences were worth $4,495,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in GILD. Swedbank AB grew its holdings in shares of Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after purchasing an additional 189,622 shares during the last quarter. OneDigital Investment Advisors LLC boosted its position in shares of Gilead Sciences by 5.1% during the third quarter. OneDigital Investment Advisors LLC now owns 32,416 shares of the biopharmaceutical company’s stock worth $2,718,000 after buying an additional 1,580 shares during the period. Coastline Trust Co acquired a new position in shares of Gilead Sciences during the third quarter worth approximately $122,000. Natixis Advisors LLC boosted its position in shares of Gilead Sciences by 18.1% during the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company’s stock worth $14,199,000 after buying an additional 25,912 shares during the period. Finally, KPP Advisory Services LLC acquired a new position in shares of Gilead Sciences during the third quarter worth approximately $206,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $111.44 on Monday. The company’s fifty day moving average is $101.82 and its two-hundred day moving average is $92.92. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a market cap of $138.78 billion, a P/E ratio of 301.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.84%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is 854.05%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.